MODERATOR(S)
Naamit Gerber, MD - NYU Langone Medical Center
session DESCRIPTION
The role of ctDNA in breast cancer is constantly evolving and expanding. This session will cover a number of topics: 1) Review the current technologies for liquid biopsy in breast cancer. 2) ctDNA in Early Breast Cancer a. rates of ctDNA detection in early stage breast cancer at diagnosis, pre- and post- neoadjuvant chemotherapy, and in the adjuvant setting. b. the utility of ctDNA in detecting MRD and predicting relapse in the adjuvant setting. c. the lead time between ctDNA detection and clinical relapse d. ongoing therapeutic trials using ctDNA in the adjuvant period. 3) ctDNA in stage IV breast cancer. a. uses of ctDNA to track disease and modify therapy b. radiation effect on ctDNA and ongoing trials in this space.
learning objectives
- Have a better understanding of the role of ctDNA in early stage breast cancer.
- Have a better understanding of the role of ctDNA in metastatic breast cancer.
- Have a better understanding of how radiation may affect ctDNA levels and ongoing studies in this space.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
12:30pm - 12:32pm ETSpeaker: Naamit Gerber, MD - NYU Langone Medical Center, Bronx
-
12:32pm - 12:52pm ETSpeaker: Maximilian Diehn, MD, PhD - Stanford University, Stanford
-
12:52pm - 01:12pm ET
ctDNA Detection Rates in the Pre-surgery, Post Neoadjuvant Therapy, Adjuvant and Follow Up Period in Non-metastatic Breast Cancer
Speaker: Heather Parsons, MD - Fred Hutchinson Cancer Center, Seattle -
01:12pm - 01:32pm ETSpeaker: Shridar Ganesan, MD, PhD - Rutgers Cancer Institute of New Jersey, New Brunswick
-
01:32pm - 01:45pm ETSpeaker: Naamit Gerber, MD - NYU Langone Medical Center, Bronx